Blog
RSS FeedPosted by Michael Wonder on 15 Jun 2022
NICE’s early value assessment for medtech: panning for nuggets of innovation gold
15 June 2022 - The explosion in digital health products has left NHS commissioners wondering how they can possibly sift out ...
Posted by Michael Wonder on 15 Jun 2022
Another week, another terminated NICE appraisal
15 June 2022 - It should not come as a surprise that it is for a cancer medicine. ...
Posted by Michael Wonder on 10 Jun 2022
Hundreds of thousands set to benefit as NICE final draft guidance recommends new treatment to prevent heart attacks and strokes in people with raised blood fats
10 June 2022 - NICE has today published final draft guidance which recommends icosapent ethyl for reducing the risk of cardiovascular ...
Posted by Michael Wonder on 09 Jun 2022
Roxadustat for treating anaemia in people with chronic kidney disease
9 June 2022 - After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Document on the ...
Posted by Michael Wonder on 08 Jun 2022
Another new month, another terminated NICE appraisal
8 June 2022 - This time it is not for a cancer medicine. ...
Posted by Michael Wonder on 07 Jun 2022
Response to engagement on proposals for the Innovative Medicines Fund
7 June 2022 - NHS England and NICE asked for comments on our proposals for the Innovative Medicines Fund. ...
Posted by Michael Wonder on 07 Jun 2022
Patients to have earlier access to cutting edge treatments on NHS
7 June 2022 - The most promising medicines will be fast-tracked to NHS patients through Innovative Medicines Fund ...
Posted by Michael Wonder on 05 Jun 2022
Values, principles, strategies, and frameworks underlying patient and public involvement in health technology assessment and guideline development: a scoping review
3 June 2022 - The importance of patient and public involvement is recognised by agencies involved in health technology assessment and ...
Posted by Michael Wonder on 01 Jun 2022
NICE recommends UCB’s Fintepla for Dravet syndrome
1 June 2022 - UCB has announced that it has received a final appraisal determination from NICE recommending Fintepla (fenfluramine). ...
Posted by Michael Wonder on 01 Jun 2022
NICE recommends potentially life-changing treatment for people with short bowel syndrome
1 June 2022 - A potentially life-changing treatment has been recommended for people with short bowel syndrome who are aged ...
Posted by Michael Wonder on 01 Jun 2022
Filgotinib maleate for patients with moderate to severe active ulcerative colitis
1 June 2022 - NICE has published evidence based recommendations on the use of filgotinib maleate (Jyseleca) for the treatment ...
Posted by Michael Wonder on 30 May 2022
NICE sets out further details on menopause guideline update
27 May 2022 - NICE has outlined what aspects of menopause care will be updated in upcoming guidance, including areas where ...
Posted by Michael Wonder on 26 May 2022
NICE recommends Libtayo (cemiplimab) for routine NHS commissioning as the first and only systemic treatment for advanced CSCC in England
25 May 2022 - NICE has published a positive Final Appraisal Determination recommending Libtayo (cemiplimab) as the first and only ...
Posted by Michael Wonder on 26 May 2022
Romosozumab for treating severe osteoporosis
25 May 2022 - NICE has published evidence-based recommendations on the use of romosozumab for patients with severe osteoporosis. ...
Posted by Michael Wonder on 25 May 2022
Target trial emulation for transparent and robust estimation of treatment effects for health technology assessment using real world data: opportunities and challenges
25 May 2022 - Evidence about the relative effects of new treatments is typically collected in randomised controlled trials. ...